<table id="id_feb9e690-ce6f-4d6d-9415-03a62d69523e" width="440.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_95cc7a15-8c4f-4514-b478-cde822209f9e">Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (<linkhtml href="#i4i_section_id_a1c9e4f9-b5e3-4173-91b6-0370db7d9bcb">2.3</linkhtml>, <linkhtml href="#i4i_section_id_19292e57-cc5a-45a2-88ac-37df0f9c16bd">2.4</linkhtml>, <linkhtml href="#i4i_contraindications_id_e233cbde-160f-4910-be90-dbdd905c5fed">4</linkhtml>, <linkhtml href="#i4i_section_id_80be185b-124e-403d-96d0-063d28e5766f">5.1</linkhtml>, <linkhtml href="#i4i_section_id_90ff3ed0-93a0-49b1-b897-047f7abac066">7.1</linkhtml>, <linkhtml href="#i4i_section_id_8b188c52-379f-4118-b795-6a37616e9061">7.2</linkhtml>, <linkhtml href="#i4i_section_id_da292296-16ef-4389-837e-7b85a6b254a5">7.3</linkhtml>, <linkhtml href="#i4i_section_id_f3821fd4-53bb-485e-b0ef-ee7f1f5bd0d3">7.8</linkhtml>, <linkhtml href="#i4i_pharmacokinetics_id_7b9c38b6-9e1d-4d29-a9c5-59206d011e8f">12.3</linkhtml>)</caption>
<col width="50.0%"></col>
<col width="50.0%"></col>
<thead>
<tr id="id_f3f722ee-0119-4bca-9f29-798cad635543">
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Interacting Agents</content>
</td>
<td align="left" stylecode="Botrule" valign="top">
<content stylecode="bold">Prescribing Recommendations</content>
</td>
</tr>
</thead>
<tbody>
<tr id="id_a1959a6b-7c11-48c5-93d2-eba6f5815820">
<td align="left" stylecode="Toprule Botrule Rrule" valign="top">Strong CYP3A4 Inhibitors, (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin,<br/> clarithromycin, telithromycin,<br/> HIV protease inhibitors, boceprevir, telaprevir, nefazodone, cobicistat-containing products), gemfibrozil, cyclosporine, danazol</td>
<td align="left" stylecode="Botrule" valign="top">Contraindicated with VYTORIN</td>
</tr>
<tr id="id_271ab2fc-3de9-4938-bee6-8729db506db2">
<td align="left" stylecode="Botrule Rrule" valign="top">Verapamil, diltiazem, dronedarone</td>
<td align="left" stylecode="Botrule" valign="top">Do not exceed 10/10 mg VYTORIN daily</td>
</tr>
<tr id="id_df516926-0ef3-4c91-8bf9-a54a3a24cf4f">
<td align="left" stylecode="Botrule Rrule" valign="top">Amiodarone, amlodipine, ranolazine</td>
<td align="left" stylecode="Botrule" valign="top">Do not exceed 10/20 mg VYTORIN daily</td>
</tr>
<tr stylecode="Botrule">
<td align="left" stylecode="Rrule" valign="top">Lomitapide</td>
<td align="left" valign="top">For patients with HoFH, do not exceed 10/20 mg VYTORIN daily<footnote>For patients with HoFH who have been taking 80 mg simvastatin chronically (e.g., for 12 months or more) without evidence of muscle toxicity, do not exceed 10/40 mg VYTORIN when taking lomitapide.</footnote>
</td>
</tr>
<tr id="id_4640007b-fdca-4064-a3e6-4e4e61012d9d">
<td align="left" stylecode="Botrule Rrule" valign="top">Grapefruit juice</td>
<td align="left" stylecode="Botrule" valign="top">Avoid grapefruit juice</td>
</tr>
</tbody>
</table>